N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=11 Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
Phase 2 N=25 Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
Chronic Pancreatitis · Insulin Resistance · Normal or Mildly Abnormal Stool Fat Levels
Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants
N/A N=24 The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly
Diabetes Mellitus, Type 2 · Insulin Resistance
Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001
Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Phase 2 N=70 Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Type 1 Diabetes
Primary: 2 Hour C-peptide AUC in Response to MMTT — 358; 495 pmol/L — p=0.81
Phase 1 N=4 Pancreatic Islet Cell Transplantation
Type 1 Diabetes
Primary: Achievement of Insulin Independence at 12-month Post Transplant — 1 participant
N/A N=39 [11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
Type2 Diabetes
Primary: [11C]5-hydroxy-tryptophan Uptake in the Pancreas — 0.17; 0.21; 0.20; 0.23 % of injected dose — p=0.5875
N/A N=168 Magnetic Resonance Imaging Study of Acute Pancreatitis
Acute Pancreatitis
Primary: The T2* Values in the Diagnosis of AP — 25.86; 21.06 ms — p=<0.01
Phase 2 N=48 Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
N/A N=19 The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
Type 1 Diabetes
Primary: Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5 — 136.8; 167.4 milligrams/deciliter (mg/dL)
N/A N=10 Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes
Hyperinsulinism · Diabetes · Pancreatic Diseases
Primary: Mean Plasma Glucose Level. — 149.666118; 162.574753 mg/dL
Phase 2 N=14 A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
Cancer of the Pancreas
Primary: Change in Serum Adiponectin Level — 34.47; 29.77 μg/ml
N/A N=4 Dietary Soy Isoflavones In Chronic Pancreatitis
Chronic Pancreatitis
Primary: Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 2 N=14 Artificial Pancreas Control System in an Inpatient Setting
Type I Diabetes Mellitus
Primary: Mean Percent of Time in Target Blood Glucose Range — 62.4 percentage of time
N/A N=32 Artificial Pancreas in Pediatric Patients (PEDarPAN)
Type 1 Diabetes
Primary: Percentage of Time Spent With Blood Glucose < 3.9 mmol/L (or 70 mg/dl) — 2; 6.7 percentage
Phase 4 N=83 Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
Pancreatitis · Diabetes
Primary: Insulin Independence — 42; 45 percentage of participants
N/A N=65 Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid
Type 2 Diabetes Mellitus
Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05
N/A N=5 Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients
Obesity
Primary: Fat Absorption — 60.6 g/d — p=<0.05
Phase 3 N=170 Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
N/A N=15 Neural-net Artificial Pancreas (NAP)
Type1 Diabetes
Primary: Percent of Time-in-Range (TIR) on NAP Versus UMPC. — 86.08; 87.25 Percent of time between 70-180 mg/dl — p=0.2
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
N/A N=148 SpHincterotomy for Acute Recurrent Pancreatitis
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
Phase 2 N=3 Allogeneic Islet Cells Transplanted Onto the Omentum
Type 1 Diabetes Mellitus · Hypoglycemia · Hypoglycemia Unawareness
Primary: A1c </= 6.5% and no Severe Hypoglycemia — 0.667 Proportion of participants
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
N/A N=174 TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Pancreatic Cancer · Pancreatitis · IPMN
Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
Phase 2 N=14 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Primary: Objective Response Rate — 0 Participants